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Summary. Treatment of neurodegenerative diseases by 
classical pharmacotherapy is restricted by blood-brain 
barrier which prevents access to the brain of potentially 
therapeutic molecules. Recent progress in the knowledge 
of pathophysiological molecular processes, and in the 
development of molecular biotechnology have opened 
the way to new therapeutic interventions for these 
disorders. This chapter reviews the most recent gene 
therapy strategies using experimental models for 
neurodegenerative diseases. 
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lntroduction 
Neurodegenerative diseases are a heterogenous and 
complex group of chronic disorders with a progressive 
evolution sharing a common pathological event: 
neuronal death. Treatment of these neurological diseases 
by classical pharmacotherapy is restricted by constraints 
specific to the nervous system. In particular, the blood- 
brain barrier prevents access to the brain of numerous 
potentially therapeutical molecules. Delivery of such 
molecules requires intracerebral or intracerebro- 
ventricular injection or infusion using osmotic mini- 
pumps when long-term treatments are required. 
An alternative strategy has been developed to 
replace degenerated neurons by transplantation of 
embryonic brain cells.  These grafts are able to 
synthesize interesting neurotransmitter for each 
pathology: dopamine for Parkinson's disease, 
acetylcholine for Alzheimer's disease or GABA for 
Huntington's disease (Sinden et al., 1992). However, this 
strategy is limited by the restricted availability of fetal 
tissue and by ethical problems in a therapeutic 
perspective. 
Recent progress in the knowledge of patho- 
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physiological molecular mechanisms involved in the 
neurodegenerative processes have permitted the 
identification of some genetic causes of many of these 
diseases (Lee et al., 1996; Hardy and Gwinn-Hardy, 
1998; Price et al., 1998;  Tran and Miller, 1999). 
Moreover, the increased development of molecular 
biotechnology has opened the way to new therapeutical 
interventions for these neurodegenerative disorders 
(Neve, 1993; Harding et al., 1997; Yeh and Perricaudet, 
1997; Corti et al., 1999). 
Gene therapy should enable neurologists to 
overcome the limitations of pharmacological treatment 
and grafting of embryonic cells. Gene transfer involves 
the introduction of a functional genetic material into a 
given brain structure for replacing a deficient gene or for 
inducing the controlled expression and release of a new 
gene with therapeutic properties (Karpati et al., 1996; 
Sabaté et al., 1996). 
Moreover, the recent development of the 
neuroimagery technology permits a precise and early 
anatomo-functional correlation for  the clinical 
evaluation of patients. 
Gene therapy approaches 
Therapeutic genes can be transferred into the 
nervous system by two different approaches: by directly 
using an appropriate vector (in vivo gene therapy) or by 
intraparenchymal grafting of genetically engineered cells 
(indirect ex vivo gene therapy) (Svendsen, 1993; Fisher 
and Ray, 1994; Ridet and Privat, 1995; Karpati et al., 
1996; Slack and Miller, 1996; Vivien et al., 1999). 
In the ex vivo approach, the therapeutic gene is 
introduced in vitro into neuronal or non-neurona1 cells, 
or into established cell lines, which are then transplanted 
to an appropriate region of the nervous system. Thus, 
this approach allows us to test the efficacy and toxicity 
of different gene vectors before cell transplantation 
(Fisher, 1995; Taylor, 1997). 
Direct gene therapy allows a local and controlled 
expression and release of therapeutic products and 
prevents the side effects associated with other 
administration routes (Le Gal La Salle et al., 1993). 
In the two approaches, the efficacy of the therapeutic 
effect resides in the optimal choice of the appropriate 
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promoter and vector for gene transfer. 
Vectors 
Therapeutic genes may be transferred to the cells by 
different types of vectors, which can be classified into 
two main groups. On the one  hand, synthet ic  
macromolecules, liposomes, lipids or cationic polymers 
carrying specific ligands for cell surface receptors. On 
the other hand, viral vectors, which are a very interesting 
tool for gene transfer into the nervous system. 
Synthetic vectors are classified in two groups: the 
cationic lipids and the cationic polymers. Both types of 
synthetic molecules are able to establish electrostatic 
links with nucleic acids (Vivien et al., 1999). Cationic 
lipids are amphiphilic molecules with a positive-charged 
hydrophil-head. These synthetic molecules, such as 
cholesterol derivatives have been shown to exhibit a 
good efficacy of infection both in vivo and in vitro. 
Cationic polymers can be peptides or other structures 
highly positive-charged. The  most interesting 
characteristic .of these molecules is that they can be 
associated to specific ligands allowing a cellular or 
nuclear targeting. However, they exhibit a low efficacy 
of transfection (Vivien et al., 1999). 
A number of viral vectors have been developed for 
central nervous system (CNS) gene transfer. Herpes 
simplex virus1 (HSVl) adenovirus, adeno-associated 
virus (AAV), retrovirus. Recently, lentivirus has largely 
been developed (Naldini et al., 1996; Slack and Miller, 
1996; Zufferey et al., 1997). Al1 vectors are replication- 
deficient virus (Kremer and Perricaudet, 1995; Slack and 
Miller, 1996). There are severa1 important points 
concerning the use of virus as vector for gene transfer 
(Karpati et al., 1996): 1) the viral tropism for certain 
cells;  2) the putative toxicity, antigenicity and 
tumorigenity of the viral genome; 3) the duration of 
expression of inserted gene; 4) the possibility of 
interaction or integration of the viral genome into the 
host genome; and 5) the facility of mass production at 
. high titers for an efficient cell transduction. 
Each viral type has advantages and disadvantages 
(Kremer and Perricaudet, 1995; Slack and Miller, 1996; 
Castro e t  al., 2000; Latchman, 2000). The  most 
important advantage of adenovirus is the safety. They 
readily infect almost total cell types in vitro and in vivo, 
and infect dividing as well as quiescent cells with a high 
efficiency. AAV and HSVl can also infect neurons with 
a high transduction frequency. Retrovirus only is able to 
infect dividing cells. The integration of the viral genome 
into the host genome, as  is  the case for AAV and 
retrovirus, can be interesting if the target is a dividing 
cell. However, this constitutes a potential risk of 
insertional mutagenesis of the transfected cells.  
Adenovirus and HSVl do not integrate into host genome 
remaining as a non replicating extrachromosomal entity 
(Kremer and Perricaudet, 1995; Slack and Miller, 1996). 
At present, adenovirus constitutes one of the most 
efficient vectors for the gene transfer into the nervous 
system (Davidson and Bohn, 1997). Adenovirus deleted 
E l  and E3 regions can accommodate large inserts of a 
high number of kilobases and can be propagated to high 
titers. However, cytotoxicity due to the viral capsid leads 
to an immune and acute inflammatory response which 
destroys transfected cells and decreases the expresion of 
the inserted gene. New strategies are being developed to 
remove al1 transcription units from the viral backbone: 
"gutless adenovirus" (Yeh and Perricaudet, 1997). 
Promoters 
Gene expression can be targeted to specific cell 
types by using appropriate promoter sequences. In the 
nervous system, an ideal promoter of a therapeutic gene 
should be active for the long-term and it should be 
tissue- or cell-specific. Thus, one can use the promoters 
for neurofilament light chain, neuron-specific enolase, 
tyrosine hydroxylase (TH) or dopamine D-hydroxylase 
for neurons, glial fibrillary acidic protein (GFAP) for 
astrocytes, myelin basic protein (MBP) for 
oligodendrocytes (Brennen et al., 1994; Karpati et al., 
1996). 
In some situations where the quantity .of the protein 
product of a transgene is  essential, the use of an 
externally regulated "inducible" promoter can be used. 
For instance, the control of gene expression in neurons 
or astrocytes can be achieved by using tetracycline- 
controlled transcriptional activation systems (tet-off 
system) (Gossen and Bujard, 1992; Corti et al., 1996, 
1999; Ridet et al., 1999). 
Route of administration 
The route of administration is a major factor in 
determining the efficiency and safety of gene therapy. 
Direct injection, preferably by stereotaxic guidance, 
has the advantage that restricted and precise regions can 
be targeted, since the spread of the vector-transgene 
construct is limited to a few millimeters. 
In order to target a neuron population in a specific 
fashion, an indirect route that uses the retrograde axonal- 
transport system is appropriate for the transfection of 
spinal pr  brainstem motoneurons (Finiels et al., 1995; 
Ghadge et al., 1995). This approach permits a selective 
and targeted transfection of motoneurons by a precise 
intramuscular injection of the vector carrying a gene of 
interest. 
Cell vehicles for gene transfer to the CNS 
Early studies used neurona1 or non-neurona1 cell 
lines as vehicles for foreign gene expression due to their 
ability to proliferate in vitro. However, because these 
cells are immortalized, th'ey continue to divide after 
transplantation and form tumors in vivo (Ridet and 
Privat, 1995; Slack and Miller, 1996). Afterwards, 
primary non-neurona1 cells (fibroblasts, myoblasts, 
astrocytes) have also been successfully used as vehicles 
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for gene transfer. In this regard, astrocytes constitute a 
promising cell vehicle for gene transfer to the CNS 
(Ridet et al, 1999). 
However, primary neurons as transgene carriers 
present a major advantage: the ability to establish 
synaptic contacts with neurons of the host tissue. In this 
way, neurons can provide a necessary gene product 
combined with a cell replacement function. Primary 
neurons have been transfected using vira1 and non-vira1 
delivery systems (Levallois et al., 1994; Vivien et al., 
1999). At present, the studies are focused on the 
transfection of immature neural precursors or stem cells 
(Martinez-Serrano et al., 1996; Wagner et al., 1999). 
Moreover, an other promising approach for CNS 
gene therapy is transplantation of polymer-encapsulated 
genetically modified cells. This technique improves graft 
survival and protects it  from immune rejection 
(Aebischer et al., 1996). 
In neurodegenerative diseases, these different gene 
transfer approaches can be used to intervene at several 
different time points in a neurodegenerative process. In a 
first phase, gene therapy can prevent neuronal 
degeneration. Once the degenerative process is 
underway, a neuroprotection strategy by neurotrophic 
factors can halt the progression of the disease. To 
encourage axonal regeneration from injured neurons, 
transplanted cells can be engineered to express growth 
factors or permissive substances. Finally, when neurons 
are irreversibly lost, cells engineered to produce 
neurotransmitters can be transplanted into denervated 
target areas to restore neuronal function. 
Alzheimer's disease 
Alzheimer's disease (AD) is the first most common 
neurodegenerative disorder. The disease is associated 
with the selective damage of brain regions and neuronal 
circuits critica1 for cognition and memory, including 
neurons in the neocortex, hippocampus, amygdala, basal 
forebrain cholinergic system, and brainstem 
monoaminergic nuclei. Dysfunction and degeneration of 
neurons in these neuronal circuits, mainly cholinergic 
innervation, lead to progressive loss of memory, 
resulting in dementia and death. 
Affected neurons accumulate tau and ubiquitin 
immunoreactivities within neurofibrillary tangles in cell 
bodies and dendrites, and in dystrophic neurites. In 
addition, patients show numerous senile plaques 
composed of dystrophic neurites displayed around 
extracellular deposits of an amyloid-J? peptide isoform 
(42 residues) that is  derived from the P-amyloid 
precursor protein (APP) (Hardy and Gwinn-Hardy, 
1998; Price et al., 1998). 
This age-associated disorder is linked to severa1 
genetic risk factors. The majority of early-onset cases of 
AD are familial and inherited as autosomal-dominant 
disorders (Lee et al., 1996). Thus, mutations have been 
identified in several genes such as presenilin genes or 
APP gene. Moreover, inheritance of the apolipoprotein 
E, apo E4 allelo constitutes a risk factor for late-onset 
sporadic AD (Lee et al., 1996). 
The first successful animal model of AD has been 
generated in mice with a plateled-derived growth factor- 
B promoter to drive the expression of a human APP 
minigene that encodes the APP-V717F substitution 
(Games et al., 1995). These mice reproduce certain 
pathological and biochemical features of AD. 
However, axotomy of the fimbria-fornix which 
induce degeneration of basal forebrain cholinergic 
neurons is the most commonly used experimental model 
of AD. Thus, the early approaches of gene therapy were 
directed to the neuroprotection of cholinergic neurons 
using this surgical model as well as aged animals where 
a memory impairment is correlated with cholinergic 
atrophy in basal forebrain nuclei. 
Since nerve growth factor (NGF) has been shown to 
prevent degeneration of adult basal forebrain cholinergic 
neurons after injury (Hefti, 1986; Williams et al., 1986), 
the attempts of gene therapy have been focused on NGF 
gene transfer to the brain by using indirect ex vivo as 
well as direct approaches. 
Indirect approaches have used primary fibroblasts, 
neural stem cells or progenitor cells which were 
genetically modified to produce NGF by retroviral 
trasduction. Then, cells were transplanted to the nucleus 
basalis of Meynert or to the media1 septum of aged rats. 
Genetically modified cell grafts were able to prevent 
spontaneous age-associated cholinergic atrophy and to 
reverse cognitive impairments of these animals (Chen 
and Gage, 1995; Martinez-Serrano et al., 1996). The 
same approach has been tested in aged primates. Aged 
monkeys received intraparenchymal grafts of autologous 
fibroblasts genetically modified to secrete NGF into 
cholinergic basal forebrain. Three months later, the loss 
of subcortical cholinergic neuronal markers in aged 
animals was nearly completely abolished by human 
NGF delivery, indicating a prevention of cholinergic 
degeneration by NGF (Smith et al., 1999). Amyloid 
plaques deposition in aged monkeys, was  not 
significantly modified by NGF delivery (Tuszynski et 
al., 1998). Similar results were observed using this 
approach in adult primates that underwent fornix 
transection to induce degeneration basal forebrain 
cholinergic neurons (Tuszynski et al., 1996). 
Direct intraparenchymal NGF gene transfer by using 
a recombinant adenovirus or an AAV was also 
performed in aged rats. A significant increase in 
cholinergic neurons ipsilateral to the injection was 
observed by choline acetyltransferase immunodetection 
(Castel-Barthe et al., 1996; Klein et al., 1999). 
A recent in vitro approach has evidenced the 
neuroprotective effect of the proto-oncogene protein 
Bcl-2 in this context. Cultured cortical neurons from 
transgenic mice expressing human Bcl-2 were partially 
protected against amyloid B-peptide-induced neuronal 
death. This neuroprotection appears to be related to the 
inhibition of amyloid B-peptide-induced apoptosis 
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(Saillé et al., 1999). 
Parkinson's disease 
Parkinson's disease (PD) is the second most common 
neurodegenerative disorder after AD. The disease is 
characterized by tremor, bradykinesia, rigidity and 
postura1 instability that result primarily from a 
degeneration of dopaminergic neurons of the nigro- 
striatal pathway. In addition to the loss of nigral neurons, 
PD is also characterized by the widespread distribution 
of intracytoplasmic eosinophilic aggregates or Lewy 
bodies. It has been suggested that Lewy bodies have a 
causative role in the degeneration. 
Most cases of Parkinson's disease occur 
spontaneously, but in a small percentage of cases, this 
disorder can be inherited in an autosomal dominant 
fashion. One form of familia1 AD has been associated 
with a missense mutation in a protein called a-synuclein 
(Tran and Miller, 1999). The function of this protein is 
unknown, but it is found in high concentrations in the 
nervous system, where it is primarily localized in nene  
terminals. It was subsequently demonstrated that a- 
synuclein is a major component of the Lewy bodies. In 
idiopathic PD, a-synuclein aggregation could be 
triggered by damage to the normal protein, through free- 
radical-mediated oxidation. The widespread detection of 
a-synuclein in many types of aggregates in different 
neurodegenerative diseases has led to the suggestion that 
it could be a common factor in initiating their formation 
(Clayton and George, 1999). However, curiously, one of 
the mutations in a-synuclein that has been linked to 
inherited PD occurs  normally in rats without 
pathological evidences (Clayton and George, 1998). 
Recently, another mutation in the enzyme ubiquitin 
carboxy-terminal hydrolase (previously associated with 
Lewy bodies) has been detected in some patients (Tran 
and Miller, 1999). 
Because no spontaneous degeneration of 
dopaminergic neurons of the nigro-striatal pathway has 
been described in animal models, experimental models 
of PD are based on surgical techniques (axotomy of 
media1 forebrain bundle) or by using specific 
neurotoxins such as 6-hydroxydopamine (6-OHDA) or 
1-methyl-4-phenyl-l,2,3,4-tetrahydropyridine (MPTP). 
Gene therapy for PD has been focused on two main 
strategies: (1) a substitutive strategy to restore levels of 
neurotransmitters by using gene encoding human 
tyrosine hydroxylase (TH), the limiting enzyme in 
catecholamine synthesis, and (2) a neuroprotective 
strategy to spare dopaminergic neurons of the substantia 
nigra by using neurotrophic factors genes.  Both 
. 
strategies can be achieved by either indirect or direct 
gene transfer approaches. 
Early ex vivo gene transfer studies used cell lines 
modified to produce TH by retroviral transduction. After 
transplantation into the denervated rat striatum by 6- 
OHDA, these engineered cells were able to reverse the 
apomorphine-induced rotation which depends on striatal 
dopamine (Horellou et al., 1990). 
More recently, primary myoblasts, fibroblasts or 
astrocytes have been the most commonly used cell types 
as vehicles for foreign gene expression. Astrocytes 
genetically modified by a retrovirus encoding TH have 
been shown to survive and express TH after 
transplantation and reduce apomorphine-induced turning 
behavior (Lundberg et al., 1996; Cortez et al., 2000). 
Primary astrocytes constitute a promising cell vehicle for 
ex vivo gene therapy for neurodegenerative diseases. A 
recent study has shown that human adult astrocytes can 
be maintained and expanded as long-term pure primary 
cultures, and can be efficiently transduced by an 
adenovirus carrying human TH gene with a tetracycline- 
controlled transcriptional activation system (tet-off 
system) (Ridet et al., 1999). This approach has been used 
for engineering human neural precursor cells which were 
then transplanted to rat denervated striatum (Corti et al., 
1999). 
A substitutive strategy for PD has also been 
achieved by direct gene transfer using synthetic or viral 
vectors of diverse nature. 
Defective viral vectors (HSV1, adenovirus or AAV) 
or cationic lipids carrying the human TH gene have been 
directly injected into 6-OHDA denervated striatum of 
rats. The expression of the transgene in the striatum 
resulted in a reduction of apomorphine-induced turning 
behavior, suggesting that TH expression partially 
restores dopamine production and behavior (During et 
al., 1994; Horellou et al., 1994; Segovia et al., 1998). 
Some attempts to apply the same approach in primates 
have been performed (During et al., 1998). 
A neuroprotective strategy has been developed by 
using trophic factors such as brain-derived neurotrophic 
factor (BDNF) or glial cell line-derived neurotrophic 
factor (GDNF), which are involved in the differentiation 
of mesencephalic dopaminergic cells. 
Thus, fibroblasts or astrocytes have been genetically 
modified to produce BDNF by retroviral transduction, 
and then transplanted into a rat denervated striatum. The 
expression of BDNF was able to prevent degeneration of 
dopaminergic neurons (Levivier et al., 1995) and to 
attenuate amphetamine-induced rotation (Yoshimoto et 
al., 1995). 
In the same way, the neurotrophic effect of an 
adenoviral vector encoding human GDNF has been 
evaluated by direct injection into the denervated 
striatum. The expression of GDNF was able to prevent 
the degeneration of dopaminergic neurons and the 
development of behavioral asymmetries which depend 
on striatal dopamine (Bilang-Bleuel et al., 1997; Choi- 
Lundberg et al., 1998) 
Transplantation of embryonic dopaminergic neurons 
has been used as an experimental strategy for PD. In 
order to ameliorate its efficacy this graft can be 
combined with a treatment of GDNF. Thus, baby 
hamster kidney (BHK) cells transfected with GDNF 
gene and encapsulated were then co-grafted with 
embryonic dopaminergic neurons into the denervated 
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striatum. The release of GDNF was able to improve 
survival and function of embryonic grafts (Tseng et al., 
1997). 
A recent and promising study has shown that neural 
stem cells derived from the mouse cerebellum can be 
transfected with the Nurr-1 gene (a transcription factor 
that mediates induction of mesencephalic dopaminergic 
neurons). Overexpression of Nurr-1 caused postmitotic 
cells to adopt a neuronal phenotype, but none of them 
exhibited TH-immunoreactivity. When Nurr-1 
overexpressing cells were exposed to a soluble signal 
secreted by type l  astrocytes from ventral 
mesencephalon, they developed into dopaminergic 
neurons. A small number of them survived after 
implantation into the adult mouse striatum (Wagner et 
al., 1999). 
Huntington's disease 
Huntington's disease (HD) is  a progressive 
neurodegenerative disorder characterized by chorea, 
involuntary movements, dystonia, intellectual 
impairment and emotional disturbances. The disease is 
associated with autosomal-dominant trinucleotide-repeat 
mutations and exhibits a neuronal loss in the striatum 
and cortex (Reddy et al., 1999; Tran and Miller, 1999). 
The gene responsible for HD has been shown to 
code for a large 350 kDa protein named huntingtin, 
which is widely distributed both within and outside the 
CNS. The molecular basis for the transmission of HD is 
associated with instability in the length of a CAG repeat 
(which codes for glutamine residues) near the N- 
terminal of the protein. Therefore, HD constitutes a good 
candidate for gene therapy strategies. 
To investigate the normal function of the HD gene, 
knockout mice have been generated. Targeted disruption 
of the murine homolog of the human HD gene was 
found to be lethal in homozygous embryos. However, 
knockout studies suggest that huntingtin is functionally 
indispensable for neurogenesis since a regionalized 
apoptotic cell death in the embryonic ectoderm has been 
observed (Reddy et al., 1999). 
In an attempt to study the basis for the instability of 
CAG trinucleotide repeats, severa1 transgenic mice were 
created. However, some of them did not show any 
degeneration or behavioral abnormalities.  In a 
fascinating experimental study carried out by Ordway et 
al. (1997), transgenic mice were generated with 146 
CAG repeats by targeting into the mouse 
phosphoribosyltransferase gene, which is not involved in 
any CAG-repeat disorder. These mice developed a 
neurodegenerative disease, clearly indicating that 
expanded polyglutamine repeat has a toxic gain-in- 
function effect. 
Although transgenic technology has recently 
developed animal models of HD, the most commonly 
used animal model is obtained by excitotoxic lesions of 
the striatum with quinolinic acid, which preferentially 
destroys medium spiny GABAergic neurons (Kordower 
et al., 1999). 
An antisense gene therapy strategy has been used to 
reduce the in vivo expression of huntingtin protein. 
However, repeated intrastriatal infusions of antisense 
oligodeoxynucleotides did not significantly reduce the 
levels of huntingtin (Haque and Isacson, 1997). 
Although the genetic basis for the HD is known the 
mechanisms involved in neuronal death occurring in this 
disease are unknown. Thus,  initial gene therapy 
approaches have been focused on a neuroprotective 
strategy. 
Studies in which NGF has been infused into the 
striatum prior to or concurrent with injections of 
quinolinic acid result in a sparing of cholinergic 
interneurons. However, cellular delivery of NGF 
potently protect both cholinergic and noncholinergic 
neurons from degeneration by excitotoxic lesion 
(Kordower et al., 1999). 
Three different cell types (fibroblasts, progenitors 
cells and stem cells) have been used for transfecting with 
the human NGF gene by retroviral transduction. Then, 
cells were grafted into the striatum prior to or after a 
quinolinic acid lesion. NGF-secreting grafts were able to 
protect diverse populations of the striatum including 
GABAergic projection neurons in this animal model. 
However, this neuroprotective effect does not seem to 
involve TrkA-specific receptor (Kordower et al., 1999). 
The neurotrophic effect of the ciliary neurotrophic 
factor (CNTF) has recently been demonstrated on a wide 
range of neurons including GABAergic, cholinergic and 
dopaminergic neurons. Thus, BHK fibroblasts were 
genetically modified to secrete human CNTF and then 
encapsulated in polymer membranes. Then, they were 
transplanted into the lateral ventricle or into the 
denervated striatum by quinolinic acid of rats or 
primates. BHK-CNTF grafts were able to preserve 
GABAergic and cholinergic neurons within the striatum, 
and to prevent aberrant motor behavior induced by the 
lesion. Moreover, BHK-CNTF grafts also protected the 
normal projection systems for this population of 
neurons, and prevented degenerative changes secondary 
to striatal degeneration in the cerebral cortex which are 
responsible for nonmotor symptoms observed in HD 
(Emerich et al., 1997; Kordower et al., 1999). 
Direct gene therapy approach has been tested by 
Bemelmans et al. (1999) in an excitotoxic rat model by 
quinolinic acid.  An intrastriatal injection of an 
adenovirus encoding BDNF was able to prevent 
degeneration of striatal GABAergic projection neurons 
induced by the lesion. 
Amyotrophic lateral sclerosis 
Amyotrophic lateral sclerosis (ALS) is an adult- 
onset neurodegenerative disease that is characterized by 
selective degeneration of motoneurons in the brainstem 
and spinal cord. This disorder leads to weakness and 
muscle atrophy, paralysis and death within three to five 
years. 
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The neuropathological features of motoneurons 
include the hyperaccumulation of phosphorylated 
neurofilaments (NF), intracellular inclusions of 
ubiquitin, and intracytoplasmic inclusions resembling 
Lewy bodies (Price et al., 1998; Tran and Miller, 1999). 
About 10% of ALS cases are inherited (familial 
ALS) with mainly an autosomal dominant pattern. 
Approximately 15-20% of patients with FALS have 
missense mutations in the gene encoding cytosolic 
Cu/Zn superoxide dismutase 1 (SODI). There is clear 
evidence of an allelic heterogeneity with associated 
phenotypes (Wong et al. ,  1998). A variety of 
chromosomal loci have been associated to forms of 
ALS. Thus, an autosomal-dominant juvenile ALS has 
been linked to loci in the 9q34 region. In patients with 
sporadic ALS, deletion mutations in the carboxy- 
terminal in the NF-H tail domain have been reported 
(Wong et al., 1998). 
There are various animal models that can in some 
way mimic an aspect of motoneuron degeneration 
characteristic of ALS. These models include neonatal 
axotomy-induced retrograde degeneration or 
spontaneously occurring murine models such as  
progressive motor neuronopathy (prnn), murine 
motoneuron degeneration (mnd), wobbler, neuro- 
muscular degeneration (nmd), paralysé, and muscle 
deficient (mdf) (Price et al., 1994; Wong et al., 1998; 
Elliott, 1999). Moreover, the identification of genetic 
factors in the aetiology of this disorder have allowed to 
generate transgenic mice that overexpress normal or 
mutated NF genes, transgenic mice expressing SODl 
mutations or gene knockout mice by gene-targeting 
strategies. 
Knockout mice with targeted deletions of both 
SODl alleles do not develop spontaneous motoneuron 
degeneration. In contrast,  transgenic mice 
overexpressing mutant S O D l  exhibit spontaneous 
motoneuron degeneration with progressive clinical 
weakness demonstrating a toxic gain-of-function for the 
mutant SODl protein in FALS (Gurney et al., 1994). 
Although the precise mechanisms underlying mutant 
S O D l  toxicity are unclear, these transgenic mice 
overexpressing mutant S O D l  provide an excellent 
animal model of human FALS. Different lines of these 
transgenic SODl mice have been generated. 
Because neurotrophic factors exhibit survival- 
promoting effects on developing motoneurons, they have 
been readily considered as potential neuroprotective 
therapeutic molecules for motoneuron degenerative 
diseases. Thus,  gene therapy approaches use 
neuroprotective strategies and al1 animal models cited 
above. 
Neonatal axotomy has been used to test an original 
strategy of selective transfection of motoneurons which 
is based on the retrograde axonal transport of an 
adenoviral vector encoding CNTF, BDNF or GDNF. 
Precise intramuscular injection of the vector prior to 
axotomy results in transgene expression in motoneurons 
afferent to the injected muscle, preventing massive 
degeneration induced by axotomy (Baumgartner and 
Shine, 1997; Giménez y Ribotta et al., 1997; Grave1 et 
al., 1997). The efficacy of this strategy based on the 
retrograde axonal transport has also been demonstrated 
in the prnn mouse. An adenovirus carrying neurotrophin- 
3 (NT-3) gene was injected into three muscles of 
neonatal prnn mice, before onset of symptoms of 
motoneuron disease. NT-3-treated animals survived 
longer than control nontreated animals and showed 
reduced loss of motor axons, and improved motoneuron 
function as assessed by electromyography (Haase et al., 
1997). Co-injection of adenovirus encoding NT-3 and 
CNTF into skeletal muscles resulted in an synergetic 
effect (Haase et al., 1997). 
An interesting strategy consists to test whether the 
overexpression of human Bcl-2 proto-oncogene protein 
or of CNTF can protect in an animal model of ALS. 
Thus, transgenic animals overexpressing Bcl-2 were 
generated and then crossed with SODl transgenic, prnn 
or wobbler mice. Overexpression of the Bcl-2 in SODl 
transgenic mice delayed the onset of the disease, 
prolonged the survival and attenuated spinal cord 
motoneuron degeneration (Kostic et al., 1997). In a 
hybrid animal carrying both human Bcl-2 transgene and 
the wobbler mutation, the pathological motoneuron 
death was not altered (Coulpier et al. ,  1996). 
Overexpression of Bcl-2 in pmn mutant mice prevented 
motoneuron loss but did not prevent degeneration of 
myelinated axons, and it did not increase the life span of 
the animals (Sagot et al., 1995). In contrast to the 
beneficia1 effects of CNTF in preventing motoneuron 
degeneration in other paradigms, the overexpression of 
CNTF in rnnd mice increased the rate of onset of motor 
disease symptoms (Winter et al., 1996). 
An ex vivo gene therapy approach has been 
developed using encapsulated BHK cells which were 
previously transfected with CNTF or GDNF gene. 
Capsules were implanted subcutaneously into the back 
of prnn mice as soon as the disease was detected. CNTF 
expression delayed the disease progression by increasing 
the survival time and by improving motor function. 
However, GDNF did not increase the life span of prnn 
mice, but significantly reduced the loss of motoneurons 
(Sagot et al., 1995, 1996). 
Finally, a phase 1 clinical study in which ALS 
patients were implanted with polymer capsules 
containing genetically engineered BHK cells releasing 
human CNTF (0.5 pglday) has been reported. Implants 
were placed within the lumbar intrathecal space. Levels 
of CNTF measured within the cerebrospinal fluid 
demonstrated a continuous delivery of CNTF by an ex 
vivo gene therapy approach (Aebischer et al., 1996). 
Retinal pathologies 
A group of inherited retina1 diseases, collectively 
termed retinitis pigmentosa (RP) is characterized by the 
progressive and specific loss of photoreceptors, the light- 
transducing neurons of the retina. Factors involved in 
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this degeneration can be genetic as well as 
environmental factors. 
Photoreceptor-specific genes directly involved in 
phototransduction have been considered primary 
candidates for RP-inducing genes. Indeed, specific 
mutations in the gene for the beta-subunit of cyclic GMP 
phosphodiesterase (B-PDE) induce dystrophies in man 
and in mice. Mutations in the gene for the structural 
protein peripherin have also been identified in mice. 
These mutant animals are useful models for 
investigation of new therapeutic strategies of gene 
therapy (Petersen Jones, 1998). 
The rd mouse is an autosomal-recessive mutant in 
which the rod photoreceptor-specific 8-PDE gene is 
altered (Cayouette et al., 1999). This mutation leads to a 
rapid and massive death of photoreceptors in 
homozygous animals by 6 weeks of age. The null 
mutation in peripherin gene in the rds mouse causes a 
protracted apoptotic loss of photoreceptors. This 
mutation has also been detected in patients affected by 
dominant forms of retinal degeneration. 
However, survival and homeostasis of photo- 
receptors are also dependent on interactions with 
adjacent cells of retinal pigment epithelium. Thus, the 
inherited photoreceptor degeneration seen in the Roya1 
College of Surgeons (RCS) rat has been attributed to a 
defect in retinal pigment epithelium (Cayouette et al., 
1999). 
Thus, rd, rds mice and the RCS rat constitute the 
current animal models to test substitutive or 
neuroprotective gene therapy strategies. 
A substitutive gene therapy strategy has been 
achieved with a vector (adenovirus, AAV or lentivirus) 
containing the gene encoding B-PDE which was directly 
injected into subretinal spaces of newborn rd mouse 
eyes. Expression of B-PDE was confirmed by two-color 
confocal immunofluorescence analysis and allowed the 
rescue of rod photoreceptor cells. Treated eyes showed a 
two-fold increase in sensitivity to light as measured by 
in vitro electroretinography (Bennett et al., 1996; Jomary 
et al., 1997; Takahashi et al., 1999). Moreover, when an 
encapsidated adenovirus mini-chromosome (from which 
al1 of the vira1 genes have been deleted) containing the 
gene encoding B-PDE was used, a prolonged transgene 
expression and a rescue of rod photoreceptor cells was 
found (Kumar-Singh and Farber, 1998). 
A neuroprotective gene therapy strategy has also 
been performed. In order to prevent photoreceptor 
degeneration, adenovirus encoding CNTF, basic 
fibroblastic growth factor (bFGF) or Bcl-2 proto- 
oncogene protein was injected into the vitreous of rd or 
rds mice or RCS rats. Expression of the transgene 
revealed a significant neuroprotective effect which 
reduced photoreceptor loss and increased the retinal 
content of the photopigment rhodopsin. These effects 
were accompanied by a significant increase in the 
amplitude of the reponse of the scotopic 
electroretinogram (Bennett et al., 1998; Cayouette et al., 
1998; Akimoto et al., 1999). 
An ex vivo gene therapy approach has been 
performed in RCS rats. Fibroblasts genetically 
engineered to secrete hFGF-2 and encapsulated in a 
biocompatible polymer were transferred into the vitrous 
cavity of animals. Secretion of hFGF-2 induced a local 
delai of photoreceptor cell degeneration (Uteza et al., 
1999). 
~ e c e n t l ~ ,  a substitution in the rhodopsin gene (codon 
P23H) has been detected in some patients with 
autosomal dominant RP. Ribozymes can discriminate 
and catalyze the in vitro destruction of P23H mutant 
mRNAs from a transgenic rat model. Intracellular 
production of ribozymes in photoreceptors was achieved 
by direct transduccion with a recombinant AAV 
incorporating a rod opsin promoter. Ribozyme-targeted 
destruction of P23H mutant mRNA considerably slows 
the rate of photoreceptor degeneration with functional 
preservation of the retina evaluated by electro- 
retinography (Lewin et al., 1998). 
Other retinal pathologies are characterized by 
retrograde degeneration of retinal ganglion cells as a 
consequence of an optic nerve lesion. This retrograde 
degeneration has been studied in a model of axotomy of 
the optic nerve and can be prevented by administration 
of neurotrophic factors. Thus, direct injection in the 
vitreous of an adenovirus encoding BDNF or GDNF was 
able to prevent retinal ganglion degeneration induced by 
axotomy (Klocker et al., 1997; Di Polo et al., 1998). 
Apoptotic cell death of retinal gangiion cells induced by 
optic nerve axotomy can be inhibited by an adenovirus 
encoding antiapoptotic protein p35 administrated at the 
optic nerve stump (Kugler et al., 1999). 
Audltory system pathologies 
Hearing impairment is a serious handicap which 
appears to be due to darnage to the peripheral auditory 
system, consisting of auditory receptors, hair cells in the 
Corti organ and spiral ganglion neurons in the cochlea. 
Therapeutic drugs including salicylates, amino- 
glycosides and chemotherapeutic agents are a major 
cause of these pathologies. 
Organotypic cultures of cochlear explants have been 
used to explore the mechanisms of action of ototoxins 
(Zheng and Gao, 1996). Using this assay the target of 
three classes of ototoxic therapeutic drugs were 
evidenced. Thus, hair cells are the the primary target of 
aminoglycosides, which can secondarily induce 
degeneration of cochlear neurons. Damage to hair cells 
was also seen after administration of chemotherapeutic 
agents, and in the case of salicylates the authors 
demonstrated that this drug was able to produce a 
selective neurona1 degeneration without hair-cell loss 
(Zheng and Gao, 1996). 
The implication of neurotrophins and their 
associated receptors for the normal development of 
afferent innervation of inner ear, has allowed the 
development of new therapeutic strategies using 
neurotrophins to treat hearing loss (Fritzsch et al., 1997). 
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Analysis of mice lacking either BDNF or its associated 
receptor, T ~ K B  have shown a reduced innervation of 
outer hair cells of the cochlea. Mice lacking either NT-3 
or its associated receptor, TncC lose many ganglion cells 
of the cochlea. In mice lacking both BDNF and NT-3 or 
both T ~ K B  and TrKC there is a complete  loss of 
innervation to the inner ear (Fritzsch et al., 1997). 
The  prevention of neurona1 degeneration by 
neurotrophins has been demonstrated by using the model 
of organotypic culture of cochlea. Thus, expression of 
NT314 or BDNF was able to protect ganglion neurons 
from degeneration induced by aminoglycosides (Ernfors 
et al., 1996; Geschwind et al., 1996). 
Direct in vivo experiments using adenovirus, AAV or 
liposomes have demonstrated successful gene transfer 
into multiple types of cochlear cells (Lalwani et al., 
1997),  and efficacy of this approach has been 
demonstrated in guinea pig cochlea. An adenovirus 
encoding the human GDNF gene was inoculated via the 
round window membrane prior to injection of 
aminoglycosides. Expression of GDNF protects hair cell 
from aminoglycoside ototoxicity (Yagi et al., 1999). 
Spiral ganglion degeneration after hair cell loss by 
aminoglycosides was prevented with a HSVl vector 
encoding BDNF (Staecker et al., 1998). 
Conclusion 
Gene therapy studies using experimental models of 
neurodegenerative diseases have shown in many cases 
successful and efficient gene transfer in ex vivo as well 
as in vivo approaches. However, there are still many 
issues to resolve before such gene transfer will be 
applicable to human diseases. Phase 1 clinical trials of 
gene therapy are still exceptional and analyze the 
requirements for an adequate feasibility and security 
rather than analyzing efficacy. The critica1 point is the 
vector. The technology is now available to create 
designer vectors that can be optimized incorporating 
features of vira1 and nonviral vectors for each 
application. The big challenge for gene therapy in 
neurodegenerative diseases is to increase the knowledge 
of the aetiopathogenesis of these disorders and to apply 
accordingly the most safe, efficient and appropiate 
targeted strategies. 
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